Ammar Sukari

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister et al. · Journal of Clinical Oncology · 2017 · 652 citations

Medicine, Oncology, Pharmacology +17

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Shirish M. Gadgeel, Nathan A. Pennell, Mary J. Fidler et al. · Journal of Thoracic Oncology · 2018 · 224 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz et al. · JAMA Oncology · 2018 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +13